Pharmaceutical Needs Assessment for Wolverhampton: 2018 - 2021 10 - PowerPoint PPT Presentation

Apr 07, 2023 •156 likes •217 views

Pharmaceutical Needs Assessment for Wolverhampton: 2018 - 2021 10 January 2018 Seeta Wakefield Public Health Registrar Our mission: Working as one to serve our city wolverhampton. gov.uk Accessibility Weekdays, 5 7 pm Walking

Pharmaceutical Needs Assessment for Wolverhampton: 2018 - 2021 10 January 2018 Seeta Wakefield Public Health Registrar Our mission: Working as one to serve our city wolverhampton. gov.uk
Accessibility – Weekdays, 5 – 7 pm Walking Public Transport See Page 22 2
Accessibility – Saturday 12 – 2pm Walking Public Transport See Pages 23 - 24 3
Accessibility – Sunday Public Transport Walking See Pages 25 - 27 4
Advanced Services 20091 2015 2018 15000 4752 2900 2071 100 112 28 0 MURS NMS AURS SACS FVS NUMSAS See 11 pharmacies 11 pharmacies 40 pharmacies 16 pharmacies 62 pharmacies 63 p harmacies Pages 32 - 35 5
Lessons Learnt / Issues Identified • Project Plan in place to replicate process in 2 years • Need to engage with HWBB earlier to increase public engagement • Lloyds Pharmacies to close 190 pharmacies nationally • Sunday access by walking from west Wolverhampton

Download Presentation

Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

Hampshire Pharmaceutical Needs Assessment Pharmaceutical Needs Assessment A statement of

Health and Wellbeing Board 15 March 2018 Hampshire Pharmaceutical Needs Assessment Pharmaceutical Needs Assessment A statement of the pharmaceutical needs of the population within the local area Is there sufficient choice with

298 views • 11 slides

Pharmaceutical Needs Assessment 2018-2021 Kirsty Hill Public Health Specialist David Bearman

Pharmaceutical Needs Assessment 2018-2021 Kirsty Hill Public Health Specialist David Bearman Devon LPC Chair What is the PNA? A Pharmaceutical Needs Assessment (PNA) is a comprehensive assessment of the current and future pharmaceutical

437 views • 21 slides

What is a Pharmaceutical Needs Assessment (PNA)? A report on the needs for pharmaceutical

What is a Pharmaceutical Needs Assessment (PNA)? A report on the needs for pharmaceutical services Identifies gaps in current and future services Identifies improvements that could be made Statutory requirement to publish every

151 views • 11 slides

UFHRD Workshop University of Wolverhampton Oct 2018 Developing impactful Practitioners through

Scholarly Practitioner Research UFHRD Workshop University of Wolverhampton Oct 2018 Developing impactful Practitioners through professional education Dr Diane Keeble-Ramsay Anglia Ruskin University Developing impactful Practitioners through

489 views • 19 slides

Establishment and Progress of the Standard System of Pharmaceutical Excipient in ChP Chinese

19/09/2018 Establishment and Progress of the Standard System of Pharmaceutical Excipient in ChP Chinese Pharmacopoeia Commission Comprehansive Division Xiaoxu Hong ChP-EDQM Workshop on Pharmaceutical Excipients 18 September 2018 Strasbourg,

365 views • 18 slides

Investor Presentation January 2018 Egypts fastest growing pharmaceutical distributor 2 nd

Investor Presentation January 2018 Egypts fastest growing pharmaceutical distributor 2 nd largest pharmaceutical distributor with a market share of c.19.2% Over 35k clients served annually through a network of 55 operational sites and a

612 views • 28 slides

Advancing Assessment: Assessment Report Capture (ARC) Assessment Institute 2018 | October 22,

UNIVERSITY OF WISCONSINMADISON Advancing Assessment: Assessment Report Capture (ARC) Assessment Institute 2018 | October 22, 2018 UW-Madison Student Learning Assessment: Context Large, public research institution, highly decentralized

197 views • 18 slides

The Scale of the Challenge: v9 Employability and Skills in Wolverhampton Overall health of the

The Scale of the Challenge: v9 Employability and Skills in Wolverhampton Overall health of the economy Commuting patterns (net flows back and forth) Travel to Work Area (TTWA) Job Density Gross Value Added (GVA) and GVA per head

377 views • 22 slides

Main Contents Relevant Background Compendial Requirements Key Points for Quality

19/09/2018 Considerations for Production and Quality Control of Animal Derived Pharmaceutical Excipients Chinese Pharmacopoeia Commission Comprehansive Division Dr. Xiaoxu Hong ChP-EDQM Workshop on Pharmaceutical Excipients 18 September 2018

203 views • 17 slides

City of Wolverhampton Council Katie Spence: Consultant in Public Health Anna Hunt Smith:

City of Wolverhampton Council Katie Spence: Consultant in Public Health Anna Hunt Smith: Consultant in Dental Public Health, PHE Our mission: Working as one to serve our city wolverhampton. gov.uk Oral health in Children: Background With

371 views • 20 slides

Pharmaceutical Misuse OMED 2018 October 8, 2018 San Diego, CA Stephen A. Wyatt, DO Medical

Pharmaceutical Misuse OMED 2018 October 8, 2018 San Diego, CA Stephen A. Wyatt, DO Medical Director, Addiction Medicine Behavioral Health Service Atrium Heath/Carolinas HealthCare System No Disclosures Objectives Background of

585 views • 29 slides

By Jan Butterworth Head of Primary Care NHS North Staffordshire September 2010 0

Pharmaceutical Needs Assessment for North and South Staffordshire Primary Care Trusts By Jan Butterworth Head of Primary Care NHS North Staffordshire September 2010 0 Pharmaceutical Needs Assessment Pharmacy White Paper 2008 highlighted

621 views • 9 slides

Continuing Professional Development (CPD) Accessible quality pharmaceutical services for all

Continuing Professional Development (CPD) Accessible quality pharmaceutical services for all OVERVIEW Legislation Framework CPD requirements Designation Annual declaration The CPD cycle Learning activities Assessment

772 views • 53 slides

Q8 (R1) - - Annex to Q8 Q8 (R1) Annex to Q8 Pharmaceutical Development Pharmaceutical

Q8 (R1) - - Annex to Q8 Q8 (R1) Annex to Q8 Pharmaceutical Development Pharmaceutical Development Robert Baum, Ph.D. Pfizer/PhRMA Public ICH Meeting 14 November 2008 Brussels, Belgium Topics to be Discussed Topics to be Discussed

388 views • 22 slides

Revision of Pharmaceutical Affairs Law (PAL) - Japan Update - Revision of Pharmaceutical

Revision of Pharmaceutical Affairs Law (PAL) - Japan Update - Revision of Pharmaceutical Affairs Law (PAL Revision of Pharmaceutical Affairs Law (PAL) was adopted by the Diet, and announced on 27 November 2013. The amendment

535 views • 14 slides

Sentiment analysis in practice Mike Thelwall University of Wolverhampton, UK Contents Creating

Information Studies Sentiment analysis in practice Mike Thelwall University of Wolverhampton, UK Contents Creating a gold standard Feature selection Cross-validation Recap The objective of commercial opinion mining is to automatically

749 views • 36 slides

Background to Sintef project Network models for EMS 1 Applications Network model (State

Background to Sintef project Network models for EMS 1 Applications Network model (State estimator) Today: 220-400 kV in Sweden. Some of 400 kV in Finland and Sealand. 70-130 kV in North and South of Sweden Future: 220-400 kV i

382 views • 4 slides

Investor Presentation March 2009 Disclaimer Certain statements in this presentation may

Investor Presentation March 2009 Disclaimer Certain statements in this presentation may constitute forward- looking statements. Such statements are subject to known and unknown risks and uncertainties that could cause the Companys actual

555 views • 42 slides

OTVCTs 2016 AGM overview 11am Welcome and Agenda for day OTVCTs 2016 overview and Q&A

OTVCTs 2016 AGM overview 11am Welcome and Agenda for day OTVCTs 2016 overview and Q&A NAV, dividends, total return Investments made during year Highlights VCT1-4 AGMs and Q&A Investee presentations: Plasma

492 views • 18 slides

Cp*Ru(PN) CATALYSTS WITH METAL/NH BIFUNCTION R 1 R 1 Ru Ru H H Ph 2 P Ph 2 P R 2 R 2 O O N

Cp*Ru(PN) CATALYSTS WITH METAL/NH BIFUNCTION R 1 R 1 Ru Ru H H Ph 2 P Ph 2 P R 2 R 2 O O N N H H R R Ph = C 6 H 5 Racemization of sec -Alcohols Lactonization of , -Diols Ru Cl Ph 2 P Isomerization of Allylic Alcohols N H

371 views • 11 slides

DNA FUNCTIONS TOMORROWS NEW HOPE AGAINST RESISTANT CANCER LISTED EURONEXT Paris NASDAQ

TODAYS SCIENCE TARGETING TUMOR DNA FUNCTIONS TOMORROWS NEW HOPE AGAINST RESISTANT CANCER LISTED EURONEXT Paris NASDAQ Copenhagen EPA: ONXEO Important Information IMPORTANT: You must read the following before continuing. In

285 views • 25 slides

Rule 4901: Wood Burning Fireplaces and Wood Burning Heaters CAC, October 7, 2008 Jessica Hafer,

Rule 4901: Wood Burning Fireplaces and Wood Burning Heaters CAC, October 7, 2008 Jessica Hafer, Senior Air Quality Specialist 1 San Joaquin Valley Air Pollution Control District Wintertime Air Pollution Human Hair (60 m diameter)

587 views • 16 slides

CLEAN AIR HAMILTON 2017 PROGRESS REPORT December 10, 2018 Hamilton Board of Health Healthy

BOH18038 CLEAN AIR HAMILTON 2017 PROGRESS REPORT December 10, 2018 Hamilton Board of Health Healthy & Safe Communities Department Matthew Lawson Public Health Services - Healthy Environments Division Manager Health Hazards Bruce

459 views • 12 slides

Starting Shortly Your details go here (24) www.equate.com 1 EQUATE Restricted EQUATE

EQUATE Group 1H 2018 Earnings Presentation August 6, 2018 Starting Shortly Your details go here (24) www.equate.com 1 EQUATE Restricted EQUATE Petrochemical Company / www.equate.com Disclaimer The content of this presentation is for

666 views • 21 slides